Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Avastin Versus Lucentis: Ethical Issues in Treatment of Age-Related Macular Degeneration

Avastin Versus Lucentis: Ethical Issues in Treatment of Age-Related Macular Degeneration Editorial Avastin Versus Lucentis: Ethical Issues in Treatment of Age-Related Macular Degeneration here is controversy over the use of ranibizumab look at the patient’s contribution to this decision-making T (Lucentis; Genentech, Inc., South San Francisco, process. CA) and bevacizumab (Avastin; Genentech, Inc.) for Retinal specialists, deciding on treatment options treating wet age-related macular degeneration (AMD), for their patients with wet AMD, have access to data the leading cause of blindness in the United States in from randomized, double-masked studies of Lucen- 2– 4 5–14 people older than 65 years of age. Evidence of this tis, observational studies of Avastin, and a large controversy is seen in journal articles, specialty meet- body of shared clinical experience. Traditionally, the ings, Internet discussions, and survey statistics. The controlled, double-masked clinical trial is the “gold American Society of Retinal Surgeons’ Preferences standard” for clinical information. However, the and Trends Survey in 2006, for example, shows a unique chronology of the introduction of these two sharp division between those ophthalmologists who drugs in treating wet AMD produced an unusual sit- prefer to treat wet AMD with Lucentis (9 –39%) and uation that, for many retinal specialists, has made the those who prefer to treat http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Retina Wolters Kluwer Health

Avastin Versus Lucentis: Ethical Issues in Treatment of Age-Related Macular Degeneration

Klein, Richard M.; Klein, Ronnie Boriskin
Retina , Volume 27 (9) – Nov 1, 2007
Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/avastin-versus-lucentis-colon-ethical-issues-in-treatment-of-age-017Lv0FAcr

References (18)

ISSN
0275-004X
eISSN
1539-2864
DOI
10.1097/IAE.0b013e31815e9322
pmid
18046218
Publisher site
See Article on Publisher Site

Abstract

Editorial Avastin Versus Lucentis: Ethical Issues in Treatment of Age-Related Macular Degeneration here is controversy over the use of ranibizumab look at the patient’s contribution to this decision-making T (Lucentis; Genentech, Inc., South San Francisco, process. CA) and bevacizumab (Avastin; Genentech, Inc.) for Retinal specialists, deciding on treatment options treating wet age-related macular degeneration (AMD), for their patients with wet AMD, have access to data the leading cause of blindness in the United States in from randomized, double-masked studies of Lucen- 2– 4 5–14 people older than 65 years of age. Evidence of this tis, observational studies of Avastin, and a large controversy is seen in journal articles, specialty meet- body of shared clinical experience. Traditionally, the ings, Internet discussions, and survey statistics. The controlled, double-masked clinical trial is the “gold American Society of Retinal Surgeons’ Preferences standard” for clinical information. However, the and Trends Survey in 2006, for example, shows a unique chronology of the introduction of these two sharp division between those ophthalmologists who drugs in treating wet AMD produced an unusual sit- prefer to treat wet AMD with Lucentis (9 –39%) and uation that, for many retinal specialists, has made the those who prefer to treat

Journal

Retina – Wolters Kluwer Health

Published: Nov 1, 2007

There are no references for this article.